Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant recipients using a joint modeling approach. by Daher-Abdi, Zeinab et al.
Impact of longitudinal exposure to mycophenolic acid on
acute rejection in renal-transplant recipients using a
joint modeling approach.
Zeinab Daher-Abdi, Marie Essig, Dimitris Rizopoulos, Yannick Le Meur,
Aure´lie Pre´maud, Jean-Baptiste Woillard, Jean-Philippe Rerolle, Pierre
Marquet, Annick Rousseau
To cite this version:
Zeinab Daher-Abdi, Marie Essig, Dimitris Rizopoulos, Yannick Le Meur, Aure´lie Pre´maud, et
al.. Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant
recipients using a joint modeling approach.. Pharmacological Research, Elsevier, 2013, 72,
pp.52-60. <10.1016/j.phrs.2013.03.009>. <inserm-00809389>
HAL Id: inserm-00809389
http://www.hal.inserm.fr/inserm-00809389
Submitted on 9 Apr 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
1 
 
Impact of longitudinal exposure to mycophenolic acid on acute rejection in renal-transplant 
recipients using a joint modeling approach 
 
Z. Daher Abdi
1,3
, M. Essig
1,2,3
, D. Rizopoulos
4
, Y. Le Meur
5
, A. Prémaud
1,3
, J.B. Woillard
1,3
,  
J.P. Rérolle
1,2
, P. Marquet
1,3,6
, A. Rousseau
1,3.
 
 
 
1
Inserm, UMR-S850, Limoges, France; 
2
Department of Nephrology, Dialysis and 
Transplantations, University Hospital Limoges, France;
 3
University of Limoges, France; 
4
Department of Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands, 
5
Department of Nephrology, University Hospital, Brest, France, 
6
Department of 
Pharmacology and Toxicology, University Hospital Limoges, France. 
 
 
Address correspondence to:  
 
Annick Rousseau; Inserm UMR-S850, Faculty of Pharmacy, 
2 Rue Dr Marcland 
87025 Limoges cedex, France; 
Phone : +33-555-43-58-95 ; Fax : +33-555-43-59-36 
Email: annick.rousseau@unilim.fr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: AR: acute rejection; AUC: area under the plasma concentration vs. time curve; CC: 
concentration-controlled; CNI: calcineurin inhibitor; CSA: cyclosporine; FD: fixed-dose; HPLC: high-
performance liquid chromatography; IMPDH II: Inosine 5' monophosphate dehydrogenase II; JM: joint model; 
MMF: mycophenolate mofetil; MPA: mycophenolic acid; PK, pharmacokinetic; PD: pharmacodynamic; RCT: 
randomized controlled trial; ROC: Receiver-operating characteristics; TDM: therapeutic drug monitoring. 
*Manuscript
Click here to view linked References
in
se
rm
-0
08
09
38
9,
 v
er
sio
n 
1 
- 9
 A
pr
 2
01
3
2 
 
ABSTRACT 
This study aimed to investigate the association between longitudinal exposure to 
mycophenolic acid (MPA) and acute rejection (AR) risk in the first year after renal 
transplantation, and to propose MPA exposure targets conditionally to this association. A joint 
model, adjusted for monitoring strategy (fixed-dose versus concentration-controlled) and 
recipient age, was developed; it combined a mixed-effects model to describe the whole 
pattern of MPA exposure (i.e. area under the concentration-time curve -AUC-) and a survival 
model. MPA AUC thresholds were determined using time-dependent Receiver-Operating 
Characteristics (ROC) curves. Data from 490 adult renal-transplant recipients, representative 
of the general population of adult renal-transplant patients (i.e. including patients considered 
at low immunological risk –enrolled in the OPERA trial- as well as second renal transplant 
and patients co-treated by either cyclosporine or tacrolimus), were analyzed. A significant 
association was found between the longitudinal exposure to MPA (MPA AUCs=f(t)) and AR 
(p=0.0081), and validated by bootstrapping. A significant positive correlation was observed 
between time post-transplantation and ROC thresholds which increased in average from 35 
mg.h/L in the first days to 41 mg.h/L beyond six months post-transplantation (p<0.001). 
Using a new modeling approach which recognizes the repeated measures in a same patient, 
this study supports the association between MPA exposure and AR. 
 
 
 
Key words:  mycophenolic acid, renal-transplant recipients, longitudinal exposure, acute 
rejection, joint modeling, ROC thresholds. 
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1. Introduction 
Mycophenolate mofetil (MMF) is an ester prodrug of the immunosuppressant mycophenolic 
acid (MPA) indicated in combination with cyclosporine (CsA) or tacrolimus to prevent 
rejection following organ transplantation.  
The role of therapeutic drug monitoring (TDM) for MPA is still debated by many physicians, 
and the controversies of its utility were recently discussed (1,2).  
Several observational studies comparing, over the first year post-transplantation, patients with 
and without T-cell mediated acute rejection (AR) found lower MPA inter-dose area under the 
plasma concentration vs. time curve (AUC) values in patients with AR (3–5) . However, a few 
other observational studies did not detect such an association between MPA AUC and 
rejection (6–8) . The association between MPA AUC and the risk of rejection has also been 
investigated in a few randomized controlled trials (RCTs), providing a higher level of 
evidence than observational retrospective studies (9,10). However, their results were also 
discordant. The Randomized Concentration Control Trial –RCCT– study (11)  compared, in 
renal-transplant patients co-treated with MMF and CsA, the incidence of AR in three patient 
groups assigned to low (MPA AUC0-12h <30 mg.h/L), intermediate (AUC0-12h = 30 to 60 
mg.h/L) or high (AUC0-12h >60 mg.h/L) MPA exposure. This trial showed a significantly 
higher incidence of AR in the low MPA exposure group and an increased incidence of 
adverse effects with no gain in efficacy in the higher exposure group, as compared to the 
intermediate group. Consequently, a 30-60 mg.h/L target window was proposed for MPA 
AUC0-12h. Two prospective randomized trials (the so-called APOMYGRE (12)  and FDCC 
(13) studies) further compared the incidence of AR in patients receiving, over the first year 
post-transplantation, either a fixed-dose (FD) regimen of MMF (1g twice daily in adults) or a 
concentration-controlled (CC) regimen adjusted to achieve a target MPA AUC0-12h (of 45 and 
40 mg.h/L in FDCC and APOMYGRE, respectively). The FDCC study (13) enrolled adult 
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and pediatric patients co-treated with CsA or tacrolimus, allowed for different analytical 
methods for MPA measurement, employed multiple linear regression for AUC estimation and 
let clinicians calculate the adjusted doses. It did not show any difference between the two 
randomization groups. However, retrospective analysis of the concentration-effect data 
showed a significant association between early MPA AUC (i.e., on day 3) and biopsy proven 
AR occurring in the first month, as well as in the first year post-transplantation. More 
specifically, a recent re-analysis of the FDCC data showed that this statistical association was 
only true in high-risk patients (i.e., patients with one or more of the following characteristics: 
delayed graft function, second or third transplantation, panel reactive antibodies >15%, four 
or more human leukocyte antigen mismatches, or of black race) (14) . In the APOMYGRE 
study (12), only adult patients co-treated with CsA were enrolled, MPA measurements were 
performed by high-performance liquid chromatography (HPLC), AUC were calculated by 
Bayesian estimation (15) and dose adjustments were computer-assisted. The median MPA 
AUCs were higher in the CC group at day 14 and at month 1, a time at which significantly 
more patients had AUC values above the target of 40 mg.h/L. A significantly higher incidence 
of AR was found in the FD group compared to the CC group (Cox model, p=0.017). 
Interestingly, there was no AR episode associated with an AUC >45 mg.h/L in the first three 
months post-transplantation. The last randomized fixed-dose vs. concentration-controlled trial 
in patients with a low immunologic risk (OPERA) (16) failed to demonstrate the benefit of 
MPA TDM: at 12 months, the overall rejection rates were similar in both groups. 
One explanation of these discrepant results might be the insufficient statistical power of some 
of these RCTs. As we previously highlighted (17), the feasibility of such a study depends 
upon: (i) compliance with the pharmacokinetic sampling time-windows; (ii) use of relevant 
tools for accurate drug exposure estimation and dose adjustment calculation; and (iii) good 
compliance of the physicians with regard to the recommended doses. One of the problems 
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with the FDCC trial (13) was probably that the proposed changes in MMF dose were not 
always appropriate, and were not performed in more than half of the cases. 
Anyway, several recent consensus conferences (18–20)  have recommended MMF monitoring 
based on MPA AUC in renal-transplant patients, mainly to overcome the problems of 
interpatient variability and time-dependent variations of MPA pharmacokinetics. Currently, 
MPA AUC is repeatedly measured in quite a number of transplantation centers (21). 
No retrospective study dealing with MMF has taken into account the drug exposure profiles 
over time in order to analyze the longitudinal exposure/efficacy relationship and determine 
optimized exposure target values for TDM. The so-called “joint” or “time-to-event” models 
can now be used to conduct such pharmacokinetic/pharmacodynamic (PK/PD) studies. These 
models were recently proposed in the biostatistics area (22–25) to analyze simultaneously a 
longitudinal outcome, such as the repeated measurement of a biomarker (e.g., the MPA AUC 
measured at different times after transplantation), and a survival outcome which is the time to 
an event of interest (e.g., AR). At this time, only one study dealing with an 
immunosuppressive drug (Belatacept) has reported a joint model to analyze the relationship 
between time-varying exposure and AR; but no significant association was found (26). 
Additionally, receiver-operating characteristics (ROC) curves specifically adapted to joint 
models have also been developed and validated; this allows calculating time-dependent 
threshold values for a time-dependent explanatory variable (27) .  
The aims of the present study were to: (i) analyze the relationship between longitudinal 
exposure to MPA and AR in the first year following renal transplantation using a joint model; 
and (ii) to determine time-dependent MPA AUC thresholds in order to minimize the risk of 
rejection. 
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2. Materials and methods 
2.1. Patients and treatment 
Data were collected from the databases of two multicenter, randomized clinical trials intended 
to investigate the clinical impact of MMF TDM in renal-transplant recipients, namely 
APOMYGRE (NCT0019967) and OPERA, and from adult renal-transplant recipients 
transplanted between 2007 and 2011 and routinely followed up at Limoges University 
Hospital. The trials complied with the Declaration of Helsinki.  APOMYGRE was approved 
by the regional ethics committee of Limoges, France; OPERA was approved by the 
Independent Ethics Committee and by the relevant authorities (EUDRACT 2006-000352-41). 
All patients were followed during the first 12 months post-transplantation (Table 1). The 
different immunosuppressive regimens employed are reported in Table 2. In APOMYGRE 
and OPERA studies, patients were randomly divided (1:1) into two groups to receive 
concentration-controlled (CC) or fixed-dose (FD) of MMF. All patients received antibody 
induction therapy (basiliximab, daclizumab, or thymoglobuline) in conjunction with dual or 
triple maintenance therapy consisting in a starting dose of 1g MMF twice daily associated to a 
calcineurin inhibitor (CNI) (i.e., CsA for APOMYGRE and OPERA patients as well as for 41 
routinely followed patients or tacrolimus for 100 routinely followed patients) and/or 
corticosteroids. All patients enrolled in OPERA were considered at low immunological risk. 
2.2. Study endpoints 
The joint models were used to model a longitudinal explanatory variable and a time-to-event 
explained process, simultaneously. Herein, the two endpoints considered were: (i) repeated 
measurements of MPA AUC within the first year post-transplantation; and (ii) AR episodes 
diagnosed in the first year post-transplantation.  
MPA was measured by high-performance liquid chromatography (HPLC) with an ultraviolet 
detector. MPA AUC values had been previously estimated in all the patients using the same 
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validated Bayesian estimators based on a three-point sampling strategy (20 min, 1 h and 3 h 
post-dose) (15). MPA AUC values were studied for each patient at different time periods 
within the first year post-transplantation (the visit times planned in each study are reported in 
Table 1) except for 7 patients who experienced AR within the first month post-transplantation 
(i.e 2, 1 and 4 patients with AR around W1, W2 and M1, respectively). For these 7 patients 
for whom a single MPA AUC measurement was available, the single observed MPA AUC 
was duplicated one day after in order to keep these patients in the analysis. On the other hand, 
patients, who did not experience AR and with a single available MPA AUC value, were 
excluded from the analysis (i.e., 26 patients from the OPERA study and 2 patients from the 
APOMYGRE trial). In total, 221 patients included in OPERA, 128 in APOMYGRE and 141 
patients routinely followed at Limoges were studied herein. Among these 490 MPA AUC 
trajectories provided, 56 were made up of only two MPA AUC values due to either 
occurrence of AR within the three first months post-transplantation (n=26) or non-compliance 
with the schedule of measurement of MPA AUC (n=30). In this later situation, patients were 
censored at the last examination time.  
MPA exposure was characterized by a wide inter-subject variability over time; coefficients of 
variation for MPA AUC calculated at each post-transplantation period ranged from 42.7% to 
45%. The median MPA AUC (as well as the AUC/Dose ratio) increased gradually over the 
first year post-transplantation, from 33.2 mg.h/L (0.014 h/L for the AUC/Dose ratio) in the 
first weeks after transplantation, up to approximately 40 mg.h/L (0.02 h/L for the AUC/Dose 
ratio)  (Figure 1). 
The AR event was diagnosed histologically on the renal biopsy. Renal biopsies were either 
performed as planned in the clinical trial or in the routine follow-up (protocol biopsies), or 
because of a clinical suspicion of AR (biopsies for cause). Biopsy proven AR was graded 
according to the Banff classification (28) . Fifty five out of 490 patients experienced an AR 
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episode in the first year post-transplantation. All were proven by histological reading of the 
renal biopsy except three (who were included in the APOMYGRE study) due to co-
administration of anticoagulants which is a contra-indication.  
2.3. Modeling framework 
Figure 2 summarizes the important steps taken in the modeling framework which are 
described here. 
2.3.1. Development of a joint model between longitudinal MPA exposure and the risk of AR  
A brief technical specification of the joint models for longitudinal and survival data that we 
employed is presented in the Supplementary Material and Methods online, but the intention 
behind it can be described with the following three-step procedure.  
In the first step, the individual trajectories of MPA AUC time-course obtained from the 
repeated estimates of AUCs collected in the first year post-transplantation (i.e., the 
longitudinal explanatory variable) are fitted using a mixed-effects model. Time was tested as 
a fixed-effect variable. Random effects were used to describe the inter-patient variability.  
In the second step, rejection-free survival was studied using a time-dependent relative risk 
model with a Weibull baseline risk function. As the incidence of AR is known to decrease 
with time, the Weibull survival distribution was assessed to describe the time-dependent 
decrease in the hazard function (29). 
The recipient age, the associated CNI, the “study” provenance (i.e., APOMYGRE/OPERA/ 
routinely followed patients) and the MMF dose-adjustment (DA) strategy used (namely FD 
and CC) were tested as covariates both in the mixed-effects sub-model (which describes the 
trajectories of MPA AUC) as well as in the survival sub-model. A covariate was retained in 
the model if its inclusion improved the log-likelihood significantly (p<0.05). 
In the third step, the mixed-effects model selected to describe the time course of MPA AUC 
was incorporated in the survival model. The resulting joint model allowed measuring the 
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strength of the association between MPA longitudinal exposure and the hazard for AR. The 
goodness-of-fit of the final joint model was checked using classically recommended 
diagnostic plots based on: (i) the marginal and subject-specific residuals for the longitudinal 
outcome; and (ii) the martingale and Cox-Snell residuals for the time-to-event outcome. The 
Cox-Snell residuals were calculated as the value of the cumulative risk function evaluated at 
the times when the event occurred. The Cox-Snell residuals plot is expected to have a unit 
exponential distribution (30). The software implementation of these joint models is the JM-R-
package described by Rizopoulos et al (22)  . 
2.3.2. Internal model validation 
The accuracy and robustness of the joint model were assessed by an internal validation, using 
a non-parametric bootstrap method. Briefly, 300 bootstrap sets were obtained by resampling 
from the original dataset, each providing estimates of model parameters. The small number of 
bootstrap datasets used is due to long computational times. The mean and 95% confidence 
interval values of each model parameter estimated from the 300 bootstrap sets were compared 
to the corresponding parameters obtained with the original dataset. This procedure was 
performed using the R software version 2.13.0 (R foundation for statistical computing, 
http://www.r-project.org). 
2.3.3. Determination of time-dependent targets of MPA exposure for individual dose 
adjustment. 
This step aims to determine the target exposure levels minimizing the risk of AR. 
We estimated time-dependent thresholds (i.e., time-varying cut-offs) of MPA exposure using 
time-dependent ROC curves adapted to a joint modeling framework (27). Traditional ROC 
analysis assumes that the explanatory variable does not change over time, which is the case 
when its measurement is performed once, at the time of diagnostic. Herein, the exposure to 
MPA varied over time and AR could occur during the course of the patient follow-up. The 
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time-dependent ROC curves used herein allowed the determination of threshold values that 
evolve over time. Thus, a different MPA AUC threshold for each post-transplantation studied 
period (days 7-14 and months 1, 3, and 6 post-transplantation) was determined by taking into 
account the shape of the MPA AUC time patterns. The 300 bootstrap samples used for the 
internal model validation were also used to determine the non-parametric 95% intervals of the 
ROC thresholds (defined by the 2.5
th
 and 97.5
th
 percentiles of the thresholds). 
3. Results 
3.1. Joint model for longitudinal MPA exposure and the risk of AR in the training 
dataset. 
A polynomial function with a quadratic term was selected to describe the trajectories of MPA 
AUCs over time. A significant improvement was obtained by inclusion of the MMF dose-
adjustment strategy as covariate in the model (i.e., fixed-dose vs concentration-controlled). 
The survival model was adjusted to the recipient age. The final longitudinal and survival sub-
models obtained were expressed in the equations (1) and (2), respectively.  
(1) Yi(tij) = β0 + β1 x tij + β2 x tij
2
 + β3 x DA + D0 + D1 x tij + D2 x DA + εi(t),    
(2) hi(t | Mi(t))= h0(t) exp [γ (Age) + α (MPA AUC (t))] 
Where: 
in (1): β0, β1, and β2 represent the mean regression coefficients estimating respectively the 
intercept, the linear and the quadratic terms of the polynomial equation of time; β3 is the mean 
regression coefficient corresponding to the effect due to the MMF dose-adjustment (DA) 
strategy; D0 and D1 the random effects for intercept and linear term of time; D2 the random 
effect for the MMF DA strategy; εi(t) the measurement errors of the longitudinal MPA 
exposure;  
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in (2): γ represents the mean regression coefficients corresponding to the explanatory variable 
“recipient age” in the hazard sub-model; and α is the coefficient measuring the association 
between longitudinal MPA exposure described by the mixed-effects model (MPA AUC (t)) 
and the hazard of AR at time t.   
The joint model obtained by combining the mixed-effects sub-model (equation 1) and the 
survival sub-model (equation 2) showed a significant association between the MPA AUC 
trajectories and AR in the first year post-transplantation (α=-0.044, p=0.0081). The risk of AR 
decreases with increasing MPA AUC value (α<0). The parameter estimates of the final joint 
model are summarized in Table 3.  
The residual plots, performed to check the goodness of fit of the joint model, are illustrated in 
Figure 3. The fitted loess curves in the plots of the standardized marginal and subject-specific 
residuals did not show any systematic error trend. Also, no systematic error trend was 
observed for the martingale residuals, indicating that the formulation chosen to describe the 
MPA AUC profiles was appropriate (30). Moreover, the unit exponential distribution seemed 
to be very close to the Kaplan-Meier estimates of the Cox-Snell residuals, and well within the 
95% confidence interval (CI), indicating a good fitting of the survival part of the joint model. 
Two hundred eighty seven out of 300 runs converged successfully in the bootstrap analysis. 
The mean bootstrap parameter estimates and their 95% confidence intervals are shown in 
Table 3. The mean of the bootstrap parameters was not statistically different from the 
parameter estimates based on the original dataset (Table 3). 
3.2. ROC analysis and time-dependent targets of MPA exposure using the final joint 
model 
The determined thresholds (with ROC AUC ≥0.55 throughout the study period) increased 
significantly with time post-transplantation: from 35 mg.h/L (2.5
th
-97.5
th
 percentiles obtained 
by bootstrap: 31-39 mg.h/L) around week 2, 37 mg.h/L (2.5
th
-97.5
th
 percentiles : 33-41 
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mg.h/L) around month 1, 40 mg.h/L (2.5
th
-97.5
th
 percentiles: 37-43 mg.h/L) around month 3, 
to 41 mg.h/L (2.5
th
-97.5
th
 percentiles: 36-43 mg.h/L) after month 6 ( quadratic correlation r² = 
0.53,  p<0.001 ).  
Figure 4 shows the distribution of MPA AUCs observed in patients exhibiting and not 
exhibiting acute rejection superimposed with the proposed ROC thresholds (and their 95% 
interval based on the 2.5
th
 and 97.5
th
 percentiles obtained using the bootstrap samples). The 
mean MPA AUCs in patients who did not experience AR were either included in this 95% 
interval of the ROC thresholds or above the upper limit of this interval (Figure 4a). All the 
patients with AR had one or several MPA AUC(s) below the ROC threshold(s) during the 
exposure follow-up (i.e. before rejection). In most of the patients, the MPA AUC observed at 
the time of diagnosis of AR was lower than the threshold proposed at the same post-
transplantation period in this study. Certain patients, however, had a MPA AUC above the 
threshold at time of diagnosis with AR but they had had low (even very low in some patients) 
MPA AUCs before the rejection as shown in figures 4b, 4c, 4d and 4e. Figure 5 shows typical 
profiles of MPA AUC-time profiles for these two kinds of patients who experienced rejection. 
4. Discussion 
Our study showed, in a large group of patients, a significant association between longitudinal 
exposure to MPA and the incidence of AR over the first year post-transplantation. 
Previously published studies dealing with the relationship between MPA exposure and AR 
were based on between-group comparisons of mean exposure at a single post-transplantation 
time (3,4,6). This method is not adapted to analyze a longitudinal exposure/efficacy 
relationship and lacks statistical power. A single AUC measurement is unable to reflect drug 
exposure over time as it does not take into account any within-patient variability associated 
with the longitudinal evolution of MPA exposure. Moreover, in some studies, MPA exposure 
was retrospectively compared at different post-transplantation times between patients who 
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had or had not experienced AR in the months which followed (5,31,32). However, in general 
no correction of the significance level for multiple comparisons was done; consequently the 
level of significance of the multiple comparisons was probably often overestimated. On the 
other hand, the randomized, controlled FD vs. CC trials were designed to investigate the 
clinical impact of MMF TDM and not the exposure/rejection relationship (11–13,16) . 
Joint models offer an efficient method to quantify the risk of AR linked to a longitudinal 
marker of exposure such as the MPA AUCs. Indeed, by relying on the individual longitudinal 
exposure, these models account for the intra-patient pharmacokinetic variability (22–25). In 
this study, the joint model used included a polynomial mixed-effects sub-model to describe 
the longitudinal evolution of MPA AUCs and a Weibull survival sub-model for the hazard of 
AR. The model was improved by introducing the MMF dose-adjustment (DA) strategy and 
the recipient age as covariates in the longitudinal and survival sub-models respectively. We 
found a significant association between MPA exposure and AR in the first year after 
transplantation. The classic diagnostic plots used (30) revealed that this model had no major 
bias and fitted the survival data well. Interestingly, the association between MPA exposure 
and AR remained statistically significant (p=0.0466) when the re-transplanted patients (n=14) 
were excluded from the database. This shows that the association also exists when only de 
novo renal-transplant patients are considered. Additionally, the database was re-analyzed after 
exclusion of the patients included in OPERA which was a study done in a population at low 
risk for acute rejection. The incidence of acute rejection was lower in OPERA than in the rest 
of the database (15/221 patients experienced acute rejection in OPERA versus 39/269 in the 
rest of the database, p=0.011).  In this complementary analysis, the association between MPA 
AUC and acute rejection remained significant (p=0.0359) in a joint model adjusted for the 
MMF dose-adjustment strategy, recipient age and co-administered CNI (i.e. cyclosporine or 
tacrolimus). Of note, in the database obtained after exclusion of the data of OPERA, 37% of 
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the patients were co-treated by tacrolimus (against only 20% in the full database), this 
explains why the co-treatment becomes a significant covariate. 
The joint model developed in the full database was used to determine MPA exposure-efficacy 
thresholds based on time-dependent ROC curves (30). The mean exposure targets obtained 
increased slightly from 35 mg.h/L in the first days to 41 mg.h/L beyond six months post-
transplantation. As shown in figure 4b, 4c, 4d and 4e, most of the patients (43/55) who 
experienced acute rejection had been under-exposed either at time of rejection or before.  
Van Gelder et al (14) previously showed a significant association between rejection and a 
measure of previous exposure (i.e. between the early MPA exposure (day 3) and the incidence 
of acute rejection in the first month and in the entire first year after renal transplantation). This 
observation suggests an increased risk of acute rejection in patients with underexposed 
periods. Non-adherence could be responsible for such underexposed periods. 
Among the 12 other patients (12/55) with rejection, 4 patients missed some visits and the 
follow-up of their exposure was interrupted far before rejection. Therefore, the value of their 
last measured AUC (above the threshold) could not reliably reflect the exposure at the time of 
AR diagnosis. Finally, only 8 patients experienced rejection (1 at M1, 5 at M3 and 2 after M6) 
despite of a full MPA AUC profile over the thresholds. 
The thresholds proposed for MPA AUC are in accordance with targets derived from RCTT 
(11)  and chosen for APOMYGRE and FDCC (12,13). For instance, in the APOMYGRE 
study, in the first three months post-transplantation, no AR occurred when the AUC nearest to 
the event was >45 mg.h/L. The proposed thresholds herein can be interpreted in terms of a 
rejection risk factor. Patients present an increased risk of rejection if their MPA exposure is 
lower than the proposed threshold. The proposed cut-offs are minimum exposure levels to 
reduce the risk of AR, but a slightly higher threshold (e.g., ≥45 mg.h/L instead of 41 mg.h/L ) 
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can be chosen in order to benefit from a secure exposure window and to favor the specificity 
of the exposure marker.  
The increase over time of the ROC thresholds obtained in the joint model is the reflect of a 
dual reality: the gradual increase of the MPA exposure observed during the first weeks post-
transplantation and the decrease over time of the target exposure of calcineurin inhibitors 
coadministered. On one hand, the AUC/dose ratio increased over time (Figure 1b) and 
concentration increase can occur despite dose-reduction. The time-dependent changes in MPA 
pharmacokinetics have been previously described. Shaw et al concluded that they result in at 
least a 30% to 50% increase in AUC0.12h during the first weeks after transplantation (33). Van 
Hest et al (34) found that the time-dependent change of exposure to MPA is caused by 
decreasing apparent clearance of MPA, due to a combination of improving creatinine 
clearance, increasing albumin, increasing haemoglobin and decreasing CsA predose 
concentrations during the first 6 months after transplantation. On the other hand, in the 
present study, as recommended, the shorter the interval after transplantation, the higher the 
target concentrations used for cyclosporine (35) and tacrolimus (36) were. This should help 
justify the use of lower target MPA exposures to adjust the immunosuppression level.  
According to the MPA thresholds proposed in our study, more than half of the patients were 
underexposed in the very first weeks post-transplantation (e.g., 61.4% of AUCs were less than 
30 mg.h/L at week 2). This result is in accordance with previous studies (12,14). Interestingly, 
in the CC sub-group, patients achieved the therapeutic target exposure faster than in the FD 
sub-group: only 30.4% had a MPA exposure less than 30 mg.h/L at week 2. However, the 
proportion of underexposed patients in both sub-groups decreased over time: 30.4% and 
28.9% had an MPA AUC <30 mg.h/L at or after 3 months post-transplantation in the FD and 
CC groups, respectively. In fact, after 3 months, patients were more likely to achieve an 
adequate MPA AUC, i.e. > 40 mg.h/L.  
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The present work provides strong new arguments in favor of a relationship between the MPA 
exposure level and the occurrence of AR in the first year after renal transplantation. However, 
this study has some limitations. First, the longitudinal exposure level to the co-administered 
CNI was not taken into account in the model while the exposure level to CsA or tacrolimus is 
also associated to the rejection risk (37–39) . It was not possible in the „JM‟ R-Package to 
investigate simultaneously the association between the longitudinal evolution of two 
quantitative variables and the onset of an event.  However, the CsA and tacrolimus doses were 
individually adjusted to reach standardized target levels. Whatever the post-transplantation 
period studied (i.e. CsA: ≤M1, M2-M3, M4-M6, M7-M12; and for Tacrolimus: ≤ M1; > M1) 
there was no significant difference between the 2-h post-dose cyclosporine mean 
concentrations or the trough tacrolimus mean concentrations obtained in patients with and 
without AR (t-test). Secondly, the joint model developed herein cannot be used for dynamic, 
subject-specific predictions of AR because the MPA exposure alone cannot predict the 
occurrence of an AR episode. Other factors than the exposure to immunosuppressive drugs 
have been shown to be associated with an alteration of the risk of AR, including delayed graft 
function (40), immunologic risks (41,42), and polymorphisms in Inosine 5' monophosphate 
dehydrogenase II (IMPDH II), a target protein of MPA (43). Thus in the OPERA trial, which 
enrolled low immunological risk patients (defined as receiving a primary renal-transplant 
from a deceased or living donor with a panel reactive antibody level of 0% and a cold 
ischemia time less than or equal to 36 h) the frequency of AR was rather low (16). 
Joint models allowed herein a novel insight into understanding the impact of the 
(longitudinal) MPA exposure on rejection risk in renal transplantation.  Such joint models are 
powerful tools for survival analysis when a time-dependent explanatory variable is measured 
intermittently. These joint models open new avenues of research for new mechanistic 
pharmacodynamics approaches.  
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In summary, the association between MPA exposure and AR in renal-transplant recipients 
was investigated in this study using a new statistical approach dedicated to the study of 
relationships between the evolution of a quantitative variable and the onset of an event. Using 
this new modeling approach based on joint models, we clearly demonstrated a significant 
relationship between MPA exposure and AR. The suboptimal statistics used in previous 
studies may explain the discrepant results which were reported. Moreover, the minimal MPA 
exposure thresholds found in the present study confirm the targets of MPA exposure chosen 
in recent randomized, comparative clinical trials, as well as the therapeutic window 
recommended in the last consensus conference on MMF monitoring (18) .  
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Figure Legends 
 
Figure 1: Distribution of mycophenolic acid area under the curve (AUC) values (a) and MPA 
AUC/Dose ratios (b) at the different post-transplantation follow-up periods (W: week, M: 
month). The line in the box is the median. The lower edge of the box represents the 25
th
 
percentile and the upper edge the 75
th
 percentile. The dotted lines in the graph (a) represent 
MPA exposure values of 30, 40 and 60 mg.h/L from bottom to top. 
 
Figure 2: Flowchart of the modeling framework 
Abbreviations: FD: fixed-dose group; CC: concentration-controlled group; AR: acute 
rejection; MPA AUC: mycophenolate acid inter-dose area under the plasma concentration vs. 
time curve. 
 
Figure 3: Residual plots based on observed data for the final joint model in the training 
dataset. The top panels (a) and (b) depict the residual plots for the diagnostic fitting of the 
longitudinal sub-model, and the bottom panels (c) and (d) depict the residual plots for the 
diagnostic fitting of the survival sub-model. The superimposed lines in the three first plots (a), 
(b) and (c) represent the fit of the loess smoother. In plot (d), the solid lines represent the 
Kaplan-Meier estimates of the Cox-Snell residual for the event process, the dotted lines 
represent the 95% confidence interval of the Kaplan-Meier estimates and the superimposed 
bold line represents the unit exponential distribution of the survival function.   
 
Figure 4: Distribution of MPA AUCs observed in patients exhibiting and not exhibiting acute 
rejection superimposed with the proposed ROC thresholds.  
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The solid dark line represents the ROC thresholds obtained from model fit, and the dashed 
dark line represent a bootstrap-based 95% interval for these thresholds.  
Figure 4a shows the mean area under the concentration time curve (AUC0-12h)  ± Standard 
Error of the Mean (–SEM-) calculated at 1 week, 2 weeks, 1, 3 and 6 months post-
transplantation in patients who do not experience acute rejection. Figures 4b, 4c, 4d, and 4e 
show the individual MPA AUC profiles (including at least 2 AUC measurements) in patients 
who experienced AR in the first month, around 3 months, around 6 months, and after 6 
months post-transplantation, respectively.  
 
Figure 5:  Typical examples of MPA AUC time-curves observed in patients who experienced 
AR: (a) patient with low MPA exposure(s) during the follow-up to the rejection and a MPA 
AUC higher than the proposed target at the time of diagnosis; (b) patient with a low MPA 
exposure at the time of diagnosis of AR. 
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 Table 1.  Demographic and clinical characteristics of the patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: D: day; M: month; SD: Standard Deviation; FD: fixed-dose group; CC: concentration-controlled 
group. 
 
 
 
 
 
 APOMYGRE OPERA 
Routinely 
followed 
patients 
Total 
Number of kidney 
transplant recipients (n) 
128 221 141 490 
Post-transplantation 
follow-up time-points  
D7, D14, M1,   
M3, M6, M12 
D14, M1, M3, 
M6, M12 
D7, D14, M1,   
M3, M6, M12 
 
- 
First transplantation (n) 125 221 130 476 
Recipient age,              
mean ± SD (years) 
49.9 ±13.8 48.3 ±13.0 51.8 ±14.8 
49.7 
±13.8 
Acute rejection         
episodes (n) 
24 16 15 55 
Time to diagnosis of acute 
rejection, mean ± SD 
(days) 
114 ±109 133 ±119 158 ±111 132 ±112 
Dose-adjustment strategy           
(n, FD/CC) 
64/64 104/117 108/33 276/214 
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Table 2.  Immunosuppressive regimen as a function of patients’ origin: the concentration-
controlled (CC) and fixed-dose (FD) groups of the APOMYGRE and OPERA clinical trials, 
and the patients routinely followed at Limoges. 
  
 
 
Abbreviations: D: day; M: month; MMF: mycophenolate mofetil; MPA AUC: mycophenolate acid inter-dose 
area under the plasma concentration vs. time curve; C2 CSA: cyclosporine (CSA) 2h post-dose (C2). 
*These patients were not enrolled in any kind of concentration-controlled clinical trial; their MPA AUCs were 
estimated using our ISBA website (https://pharmaco.chu-limoges.fr). 
 
 
 
 
 
 
 
Study APOMYGRE OPERA Routinely followed patients* 
Induction therapy basiliximab  basiliximab or daclizumab basiliximab or thymoglobuline 
 
Maintenance therapy 
 
-500 mg of i.v methylprednisolone 
on day 0 followed by 1mg/kg/day 
of prednisolone on days 1-7, 0.5 
mg/kg/day on days 8-14, then 
reduced weekly until discontinued 
if possible 
 
-8 +/- 2mg/kg/day of cyclosporine 
within 3 days post-transplant and 
adjusted to maintain C2 levels of 
1300-1500 ng/ml through week 4, 
1100-1300 ng/ml months 2-3, 900-
1100 ng/ml months 4-6 and 800 
ng/ml months 7-12 
 
 
 
 
 
- 1g twice daily of MMF in the FD 
group, and 1g twice daily of MMF 
in the CC group until day 7 and 
then adjusted to reach an MPA 
AUC target of 40 mg.h/L 
 
-500 mg of iv methylprednisolone on 
day 0 followed by 0.5 mg/kg/day of 
prednisolone until day 7 
 
 
 
 
-cyclosporine was administered 
within 3 days post-transplant with 
the dose adjusted to maintain C2 
levels of 1000-1500 ng/ml through 
week 4, 800-1200 ng/ml weeks 4-12, 
500-800 ng/ml weeks 12-52. 
 
 
 
 
 
 
- 1g twice daily of MMF in the FD 
group, and 3g/day of MMF in the CC 
group until day 10 and then adjusted 
to a target MPA AUC of 40 mg.h/L. 
 
-500 mg of iv methylprednisolone 
on day 0 followed by 125 mg of 
prednisolone on day 1, 20 mg on 
days 2-15, and then reduced 
weekly until month 3. 
 
 
-0.15 mg/kg/day of tacrolimus or 
5mg/kg/day of cyclosporine 
within 3 days post-transplant.  
CSA C2 target levels were 1000-
1500 ng/ml through week 4, 800-
1200 ng/ml weeks 4-12, 500-800 
ng/ml weeks 12-52. 
Tacrolimus trough levels were 8-
12ng/mL through week 4 then 6-
8 ng/mL. 
 
 
- 1g twice daily of MMF in the FD 
group, and 1g twice daily of MMF 
in the CC group and then 
adjusted in the first week to 
reach an MPA AUC target 
between 30 and 60 mg.h/L. 
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Table 3.  The parameter estimates and bootstrap results of the final joint model. 
 
Parameters 
Final model results Bootstrap results                  
(n=300 samples)   
Estimates (se) P value Mean estimates  95% CI 
 
 
Longitudinal 
sub-model 
β0  (Intercept) 33.6 (0.8) <0.001 37.6  37.5; 37.7 
β1 (Time) 18.2 (3.4) <0.001 17.9  17.7; 18.2 
β2 (Time x Time) -15.7 (3.4) <0.001 -15.2  -15.4; -15.1 
β3 (DA) -2.5 (1.0) 0.0187 -2.4  -2.5; -2.3 
 
Survival 
sub-model 
γ (Age) -0.0088 (0.01) 0.4025 -0.012 -0.016; -0.0081 
α (MPA AUC (t)) -0.044 (0.017) 0.0081 -0.053 -0.055 ; -0.051 
*Intercept 0.13 (0.83) 0.8733 0.39  0.32 ; 0.45 
*Log(scale) -0.19 (0.12) 0.1264 -0.17 -0.19 ; -0.16 
 
Variance 
Components 
D0 8.3 _ 7.9  7.8; 8.1 
D1 6.6 _ 7.2 7.0; 7.4 
D2 11.8  12.0 11.8; 12.2 
D01 -0.39 _ -0.38  -0.40; -0.35 
D02 -0.49 _ -0.48 -0.50; -0.46 
D12 0.11 _ 0.12 0.094; 0.14 
Ԑ 14.2 _ 14.1 14.0; 14.2 
 
N.B. β0, β1, β2, and β3 represent the mean regression coefficients of the longitudinal sub-model. γ1, γ2,  and α 
represent the mean regression coefficients of the survival sub-model. D0 denotes the variance of the random 
intercept, D1 the variance of the random linear term of time effect, D2 the variance of the effect due to the 
dose-adjustment strategy; and D01, D02 and D12 their covariances. ε denotes the residual error corresponding 
to the measurement errors. (*) Intercept and log scale are the two parameters defining the Weibull baseline 
function (ho(t)).  
se: standard error; CI: confidence intervals; DA: dose-adjustment strategy, MPA AUC(t): mycophenolate acid 
inter-dose area under the plasma concentration vs. time curve. 
 
 
 
 
 
 
in
se
rm
-0
08
09
38
9,
 v
er
sio
n 
1 
- 9
 A
pr
 2
01
3
Supplementary Material and Methods 
 
The joint model framework used in this study has been described by Rizopoulos et al 
 
(1) and 
can be formulated briefly in the following 3 steps: 
 The longitudinal sub-model  
The “true unobserved” (i.e., theoretical) trajectory of the biomarker is described by a mixed-
effects model which can be expressed as:  
Yi(t) | bi = mi(t) + εi(t) 
              = xi
T(t)β + zi
T
(t) bi + εi(t),   εi(t) ~ N(0, σ
2
)    
Where : 
 Yi(t) denotes the observed available measurements of the biomarker at time point t for 
the i
th
 subject 
 xi(t) and β represents the mean response (i.e., fixed effect), with xi the explanatory 
variable and β its corresponding regression coefficient.    
 zi(t) and bi represents the subject-specific variability (i.e., random effect), with zi(t) the 
random variables and bi their corresponding coefficient,  bi(t) ~ N(0, D).  
  εi(t) is the measurement error of the longitudinal outcome, with variance σ
2
 
Basically, in the mixed-effects model, all the individual profiles are described using the same 
mathematical equation (i.e., fixed effects), but due to the inter-patient variability (i.e., random 
effects), the coefficient values used in the equation are different for each patient, allowing 
thereby for different patient-specific profiles in time. 
 The survival sub-model  
The survival sub-model is described as a time-dependent relative risk model using a baseline 
risk function:   
                      hi (t | Mi(t)) = h0(t) exp {γ
T
 wi + α mi(t)}  
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Where: 
 h0(t) is the baseline risk function.  Several different options including both parametric 
(i.e., Weibull, piecewise-constant, B-splines) or semi-parametric (i.e., Cox) models are 
available for h0(t) in the JM package.  
 Mi(t) = { mi(s), 0≤s<t} denotes the theoretical, unobserved biomarker history up to 
time t. The true trajectory of the biomarker at time t (mi(t)) is obtained using the mixed-
effects longitudinal sub-model described above. 
 α quantifies the effect of the biomarker on the hazard for the event. It measures the 
strength of the association between mi(t) that denotes the true level of the biomarker at 
time t, and the hazard for an event at the same time point. 
 Wi is a vector of baseline covariates (such as a treatment indicator, age …) with a 
corresponding vector of regression coefficients γ. 
 The joint model 
The two processes (survival sub-model and longitudinal sub-model) are combined using joint 
log-likelihood estimation. This joint distribution between the two processes assumes that both 
sub-models share the same random effects (conditional independence assumptions).  
In order to fit the joint model, the objects returned by the mixed-effects sub-model and the 
survival sub-model were used as the main arguments in the joint model, also called “time to 
event model”. The Gauss Hermite integration rule was used for the maximization of the joint 
log-likelihood function.  
 
(1) Rizopoulos, D. JM: an R package for the Joint Modeling of Longitudinal and Time-to-
event Data. J. Stat. Softw. 35, 1-33 (2010). 
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